Investors

annual report

No items found.

shareholder newsletter

Radiopharm Newsletter March 2022 - Meet our CEO in Australia

March 2022
Download

Radiopharm Theranostics Newsletter Dec 2021

December 2021
Download

ANalyst coverage

Bioshares RAD Update 17 June 2022

June 2022
Download

Bioshares - RAD Update 3 June 2022

June 2022
Download

Diamond Equity Research - Valuation at 87 cents per share - Another meaningful addition to the Pipeline

June 2022
Download

Diamond Equity Research increases valuation to 87 cents per share - Transformative acquisition and progress in clinical trials to drive value

April 2022
Download

Diamond Equity Research Report Feb 2022

February 2022
Download

Diamond Equity Research initiates coverage with valuation 84 cents per share Jan 2022

January 2022
Download

Radiopharm (ASX:RAD) - Independent Investment Research initiates coverage with valuation of 86 cents per share

December 2021
Download

corporate governance

Radiopharm Theranostics Prospectus and Supplementary Disclaimers

Download

Radiopharm Theranostics Prospectus

Download

Radiopharm Theranostics Supplementary Prospectus

Download

Corporate Governance

Download

corporate policies

Privacy Policy

Download

Sign up to our mailing list.

Receive all the latest news from Radiopharm Theranostics.